Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis

ABSTRACT

Purpose

To evaluate the efficacy of the fluocinolone acetonide intravitreal implant (Yutiq) as monotherapy for uveitis.

Design

Retrospective cohort study.

Participants

Patients at a single academic health-care institution.

Methods

Medical record review of patients with non-infectious uveitis actively suppressed on an alternative anti-inflammatory regimen who received a fluocinolone acetonide implant. The primary outcome was continued control of inflammation based on clinical examination, optical coherence tomography, and fluorescein angiography.

Results

Thirteen patients (19 eyes) received an implant. Median follow-up was 6 months. Uveitis control was achieved in 14 eyes (74%), though three (21%) required a topical steroid after insertion. The remaining five eyes (26%) required additional intraocular treatments.

Conclusion

The fluocinolone acetonide implant may not suffice as monotherapy for all patients with uveitis, but it may be effective as an adjunctive treatment. We propose a clinical workflow for the selection and treatment of patients who may benefit from it.

KEYWORDS:

• Fluocinolone acetonide
• inflammatory control
• intravitreal implant
• monotherapy
• uveitis

View correction statement:

Correction

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported in part by unrestricted grant funding from All May See Foundation (San Francisco, CA) and Research to Prevent Blindness (New York, NY) to the University of California, San Francisco, Department of Ophthalmology.